Table 2.
Univariate analyses of CSS in ESCC patients.
| 5-year CSS | Mediean (M) | P-value | HR (95% CI) | P-value | |
|---|---|---|---|---|---|
| Age (years) | 0.997 | 0.997 | |||
| ≤ 60 | 30.5% | 32 | 1.000 | ||
| > 60 | 32.1% | 32 | 1.000 (0.780-1.280) | ||
| Gender | 0.950 | 0.951 | |||
| female | 31.8% | 28 | 1.000 | ||
| male | 31.0% | 32 | 1.009 (0.756-1.348) | ||
| Tumor length (cm) | 0.003 | 0.004 | |||
| ≤ 3.0 | 39.6% | 48 | 1.000 | ||
| > 3.0 | 27.8% | 27 | 1.522 (1.147-2.021) | ||
| Tumor location | 0.381 | 0.392 | |||
| upper | 44.0% | 45 | 1.000 | ||
| middle | 29.1% | 32 | 1.471 (0.846-2.558) | 0.172 | |
| lower | 31.4% | 32 | 1.402 (0.806-2.439) | 0.231 | |
| Vessel invasion | 0.015 | 0.017 | |||
| negative | 33.3% | 36 | 1.000 | ||
| positive | 20.0% | 20 | 1.469 (1.073-2.013) | ||
| Perineural invasion | 0.006 | 0.007 | |||
| negative | 34.1% | 39 | 1.000 | ||
| positive | 20.3% | 20 | 1.486 (1.117-1.977) | ||
| Smoking | 0.265 | 0.271 | |||
| no | 34.0% | 35 | 1.000 | ||
| yes | 27.8% | 27 | 1.148 (0.898-1.467) | ||
| Drinking | 0.606 | 0.610 | |||
| no | 30.3% | 36 | 1.000 | ||
| yes | 32.6% | 25 | 1.068 (0.830-1.375) | ||
| Differentiation | 0.142 | 0.150 | |||
| well | 38.5% | 35 | 1.000 | ||
| moderate | 30.9% | 34 | 1.118 (0.766-1.631) | 0.564 | |
| poor | 27.0% | 16 | 1.461 (0.943-2.263) | 0.089 | |
| TNM stage | <0.001 | <0.001 | |||
| I | 48.9% | 67 | 1.000 | ||
| II | 33.6% | 34 | 1.697 (1.185-2.430) | 0.004 | |
| III | 18.9% | 19 | 2.784 (1.995-3.886) | <0.001 | |
| CRP (mg/L) | <0.001 | <0.001 | |||
| ≤ 10.0 | 36.7% | 42 | 1.000 | ||
| > 10.0 | 15.5% | 17 | 2.060 (1.581-2.685) | ||
| ALB (g/L) | <0.001 | <0.001 | |||
| ≥ 35.0 | 35.0% | 40 | 1.000 | ||
| < 35.0 | 15.3% | 20 | 1.979 (1.480-2.645) | ||
| NLR | <0.001 | <0.001 | |||
| ≤ 6.0 | 34.4% | 36 | 1.000 | ||
| > 6.0 | 10.2% | 20 | 2.029 (1.464-2.812) | ||
| LDH (U/L) | <0.001 | <0.001 | |||
| ≤ 240 | 35.8% | 39 | 1.000 | ||
| > 240 | 16.7% | 20 | 1.767 (1.348-2.315) | ||
| GRIm-Score | <0.001 | <0.001 | |||
| low | 35.0% | 39 | 1.000 | ||
| high | 10.3% | 18 | 2.246 (1.652-3.054) | ||
| Adjuvant therapy | 0.129 | 0.133 | |||
| No | 32.3% | 38 | 1.000 | ||
| Yes | 28.7% | 23 | 1.223 (0.940-1.591) |
ESCC: esophageal squamous cell carcinoma; CSS: cancer-specific survival; GRIm-Score: Gustave Roussy Immune Score; CRP: C-reactive protein; ALB: albumin; LDH: lactate dehydrogenase; TNM: tumor node metastasis; NLR: neutrophil to lymphocyte ratio; CI: confidence interval; HR: hazard ratio.